Global Biosimilar Monoclonal Antibodies Forecast 2020-2030
Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027
- Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
- Infliximab
- Rituximab
- Abciximab
- Trastuzumab
- Adalimumab
- Bevacizumab
- This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
- Remsima/Inflectra
- Infimab
- Reditux
- BI695500
- CT-P10
- BI695501
- FKB327
- FKB238
- Mabtas
- AcellBia
- Maball
- Clotinab
- Abcixirel
- BCD-022
- BCD-021
- Herzuma
- CANMAB/Hertraz
- Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
- The US Biosimilar mAb Market
- Japanese Biosimilar mAb Market
- EU5 Biosimilar mAb Markets
- BRIC and South Korea Biosimilar mAb Markets
- Rest of the World Biosimilar mAb Market
- This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline
- Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Overview of Biosimilar Monoclonal Antibodies: R&D, Industry and Market
- 1.2 Why You Should Read this Report
- 1.3 How This Study Delivers
- 1.4 Main Questions Answered by the Analysis
- 1.5 Who is This Investigation For?
- 1.6 Method of Research and Analysis
- 1.7 Frequently Asked Questions (FAQs)
- 1.8 Associated Visiongain Reports
- 1.9 About Visiongain
- 2. Introduction to Biosimilar Monoclonal Antibodies
- 2.1 Natural Antibodies: Key to the Immune System
- 2.2 From Serum therapy to Monoclonal Antibodies
- 2.3 Humanising the mAb
- 2.4 Biologics (Biological Drugs) and Biosimilars
- 2.5 Why are Biosimilars in High Demand?
- 2.6 Considerations for the Development of Biosimilars
- 2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
- 2.6.2 How Much of a Concern is Immunogenicity?
- 2.7 Biosimilar Monoclonal Antibodies Currently on the Market
- 3. The Global Market for Biosimilar Monoclonal Antibodies, 2016-2027
- 3.1 The Present Global Market for Biosimilar Monoclonal Antibodies
- 3.2 The Global Market for Biosimilar mAbs: A Revenue Forecast, 2016-2027
- 3.3 The Global Market for Biosimilar mAbs by Compound: Predictions for Revenue and Market Share in 2020 and 2027
- 3.4 The World Market for Biosimilar mAbs by Compound: Revenue Forecasts, 2016-2027
- 3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
- 3.4.2 Biosimilar Infliximab: Currently the Second Largest Submarket
- 3.4.2.1 Biosimilar Infliximab Revenue Forecast 2016-2027
- 3.4.3 Biosimilar Rituximab: The Current Leading Submarket Driven by Sales in Russia
- 3.4.3.1 Biosimilar Rituximab: Revenue Forecast 2016-2027
- 3.4.4 Biosimilar Abciximab: Revenue Forecast 2016-2027
- 3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2016-2027
- 3.4.5 Biosimilar Trastuzumab: Pipeline Rich in Phase III Candidates
- 3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2016-2027
- 3.4.6 Biosimilar Adalimumab: Patents Hold Back Revenue on a Large Pipeline
- 3.4.6.1 Biosimilar Adalimumab: Revenue Forecast 2016-2027
- 3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Biosimilar mAb Market Restrict Revenue?
- 3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2016-2027
- 3.5 Drivers and Restraints for the Biosimilar mAb market 2016-2027
- 3.5.1 Driving Factors of the Biosimilar mAb Market 2016-2027
- 3.6 Restraining Factors of the Biosimilar mAb Market 2016-2027
- 4. Individual Biosimilar mAb Products: Marketed and Pipeline Drugs, 2016-2027
- 4.1 Biosimilar mAbs on the Market in 2017
- 4.1.1 Celltrion’s Remsima/ Hospira’s Inflectra. Egis’ Flammegis (Infliximab): The First Official Biosimilar Monoclonal Antibody
- 4.1.1.1 Remsima/Inflectra/Flammegis Revenue Forecast, 2016-2027
- 4.1.2 Infimab (Infliximab): Launched a Quarter Ahead of Schedule
- 4.1.2.1 Infimab Revenue Forecast ($m) 2016-2027
- 4.1.3 Dr Reddy’s Reditux (Rituximab): No Application for EU or US Approval
- 4.1.3.1 Reditux Revenue Forecast, 2016-2027
- 4.1.4 Intas Pharmaceuticals’ Mabtas (Rituximab)
- 4.1.4.1 Mabtas (Rituximab) Revenue Forecast 2016-2027
- 4.1.5 AcellBia (Rituximab): Sales in Russia Generating Large Revenue Figures
- 4.1.5.1 AcellBia Revenue Forecast 2016-2027
- 4.1.6 MABALL: Faces Competition from other Biosimilar Rituximabs in India
- 4.1.6.1 MABALL Revenue Forecast, 2016-2027
- 4.1.7 Isu Abxis’ Clotinab (abciximab):
- 4.1.7.1 Clotinab Revenue Forecast, 2016-2027
- 4.1.8 AbcixiRel: The First Indian Abciximab Biosimilar
- 4.1.8.1 AbcixiRel Revenue Forecast 2016-2027
- 4.1.9 Herzuma (Trastuzumab): Approved in South Korea
- 4.1.9.1 Herzuma Revenue Forecast 2016-2027
- 4.1.10 CANMAb/Hertraz (Trastuzumab)
- 4.1.10.1 CANMAb/Hertraz Revenue Forecast, 2016-2027
- 4.2 Pipeline Biosimilars
- 4.2.1 BI695500 (Rituximab): An EU Launch Anticipated in 2017
- 4.2.1.1 BI695500 Revenue Forecast, 2016-2027
- 4.2.2 CT-P10 (Rituximab): Celltrion’s Reputation for Biosimilars will Assist Sales
- 4.2.2.1 Celltrion’s CT-P10 (Rituximab) Revenue Forecast, 2016-2027
- 4.2.3 Boehringer Ingelheim’s BI695501 (Adalimumab)
- 4.2.3.1 BI695501 Revenue Forecast, 2016-2027
- 4.2.4 BCD-022 (Trastuzumab): Currently under Development in Russia Only
- 4.2.4.1 BCD-022 Revenue Forecast, 2016-2027
- 4.2.5 Fujifilm Kyowa Kirin Biologics’ FKB327 (Adalimumab)
- 4.2.5.1 FKB327 Revenue Forecast, 2016-2027
- 4.2.6 Fujifilm Kyowa Kirin Biologics’ FKB238 (Bevacizumab)
- 4.2.6.1 Fujifilm Kyowa Kirin Biologics’ FKB238 Revenue Forecast 2016-2027
- 4.2.7 BCD-021 (Bevacizumab): Russia Will Contribute the Most Revenue
- 4.2.7.1 BCD-021 Revenue Forecast 2016-2027
- 5. Leading National Markets for Biosimilar Monoclonal Antibodies
- 5.1 What Were the Leading National Markets for Biosimilar mAbs in 2016?
- 5.2 How Will National Market Shares Change Over the Forecast Period?
- 5.3 India: The Current Leading Nation for Biosimilar mAbs but Growth will Slow
- 5.3.1 India Releases New Biosimilar Development Guidelines
- 5.3.2 Indian Biosimilar Submarket Forecast 2016-2027
- 5.4 Russia: Lack of Regulatory Framework Works Well in the Short Term
- 5.4.1 Russian Government Backed ‘Pharma 2020’ Initiative
- 5.4.2 Russian Biosimilar mAb Revenue Forecast, 2016-2027
- 5.4 South Korean Market has Benefitted from Early Biosimilar Guidelines
- 5.4.1 Significant Investment in Biosimilars in South Korea
- 5.4.2 South Korean Biosimilar mAb Revenue Forecast, 2016-2027
- 5.5 China: A Fragmented Biosimilar mAb Market
- 5.5.1 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2015
- 5.5.2 China Biosimilar mAb Revenue Forecast, 2016-2027
- 5.6 Brazil: ANVISA’s Biosimilar Regulations Are Similar the EMA’s
- 5.6.1 Brazil Biosimilar mAb Revenue Forecast 2016-2027
- 5.7 The Outlook for Biosimilar mAbs in the EU 2016-2027
- 5.7.1 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar mAbs
- 5.7.2 Biosimilar mAbs in the EU5: Revenue Forecasts, 2016-2027
- 5.7.3 Germany: The Current EU Leader
- 5.7.4 France: Will the Uptake of Biosimilar mAbs be Restricted?
- 5.7.5 UK: NICE Recommends Use of Remsima for Certain Indications
- 5.7.6 Italy: Healthcare Spending Cuts Will Drive Growth
- 5.7.7 Spain: High Biosimilar mAb Discounts Expected
- 5.8 The Outlook for Biosimilar mAbs in Japan
- 5.8.1 Regulations for Naming Biosimilars
- 5.8.2 Biosimilar mAb Market Activity in Japan
- 5.8.3 Japanese Biosimilar Submarket Forecast 2016-2027
- 5.9 US Biosimilar mAb Outlook: None Currently on the Market
- 5.9.1 US FDA Biosimilar Guidelines were Released in 2015
- 5.9.2 Legal Challenges for Biosimilars in the US
- 5.9.3 State Regulation of Biosimilar Substitution
- 5.9.4 The US Biosimilar mAb Market Revenue Forecast, 2015-2027
- 6. Leading Companies in the Biosimilar Monoclonal Antibodies Market
- 6.1 Collaboration in Biosimilar mAb Development
- 6.2 BioXpress: Targeting Patent Expiry Dates in 2019-2023
- 6.3 Celltrion: Company’s Market Value Surges to Exceed $10.7bn
- 6.4 Harvest Moon: Six Compounds Under Development
- 6.5 Genor Biopharma: A Biosimilar mAb Market Leader in China
- 6.6 Samsung Bioepsis
- 6.7 Mabion: Poland’s Leading Biosimilar mAb Developer
- 6.8 Gene Techno Science: Substantial Revenue Increases Since 2014
- 6.9 India’s Biocon:
- 6.10 Coherus Biosciences
- 6.11 BIOCAD: World Leader Biosimilar Rituximab Sales
- 6.12 Big Pharma and the Biosimilar mAb Market
- 6.13 Significant Acquisitions in the Biosimilar mAb Market
- 6.13.1 Pfizer Acquires Hospira
- 6.13.2 Epirus Acquires Bioceros
- 7. Qualitative Analysis of Biosimilar Monoclonal Antibodies Market
- 7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibodies Market, 2016-2027
- 7.1.1 Global Demand for Affordable Biopharmaceuticals has Never Been Greater
- 7.1.2 Adoption of Biosimilar mAbs will be Proportional to the Rate of Discount
- 7.1.3 Approval Pathways are Now Established in Developed Markets
- 7.1.4 Complexity of Protein Molecules Leads to Technical Challenges
- 7.1.5 Doctor and Patient Confidence May Take Time
- 7.2 Opportunities and Threat Facing the Biosimilar Monoclonal Antibodies Market, 2016-2027
- 7.2.1 Market Opportunities from Patent Expiries and a Well-stocked Pipeline
- 7.2.2 Substitution may Not Occur Automatically
- 7.2.3 Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
- 7.3 Social and Technological Forces Influencing the Biosimilar Monoclonal Antibodies Market 2016-2027
- 7.3.1 Social Factors: Driving or Restraining the Market?
- 7.3.2 Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
- 7.3.3 Economic Pressures Raise Demand for Biosimilar mAbs
- 7.3.3.1 Fragmentation of the Market Could Limit Individual Drug Revenues
- 7.3.4 Political Issues: Stringent Regulations Hurdles to Market Entry
- 8. Conclusions
- 8.1 Biosimilar Monoclonal Antibodies: World Market, 2016-2027
- 8.2 Future of Compounds on the Market and in the Pipeline
- 8.3 Leading National Markets for Biosimilar Monoclonal Antibodies 2016-2027
- 8.4 Leading Companies in the Biosimilar mAb Market
- 8.5 Current and Expected Industry Trends 2016-2027
- 8.5.1 Cost Control of Healthcare Will Work in Favour mAbs
- 8.5.2 Upcoming Patent Expiries in Developed Markets Offer Large Market Potential
- 8.5.3 Complex Production Processes are a Restraining Factor
- 8.5.4 Clinician and Patient Confidence Must be Maximised to Ensure Uptake
- 8.5.5 Biobetters Pose a Threat
- Visiongain Report Sales Order Form
- Associated Visiongain Reports
- About Visiongain
- Visiongain report evaluation form
- List of Figures
- Figure 1.1 Main Compound Classes of Biosimilar mAbs, 2017
- Figure 2.1 Structure of an Antibody
- Figure 3.1 Global Market for Biosimilar mAbs: Revenue forecast ($m), 2016-2027
- Figure 3.2 The Biosimilar mAb Market: Market Share (%) by compound in 2017
- Figure 3.3 The Biosimilar mAb Market: Market Share (%) by compound in 2020
- Figure 3.4 The Biosimilar mAb Market: Market Share (%) by compound in 2027
- Figure 3.5 Biosimilar Infliximab: Global Revenue ($m) Forecast 2016-2027
- Figure 3.6 Biosimilar Rituximab: Global Revenue ($m) Forecast 2016-2027
- Figure 3.7 Biosimilar Abciximab: Global Revenue ($m) Forecast 2016-2027
- Figure 3.8 Biosimilar Trastuzumab: Global Revenue ($m) Forecast 2016-2027
- Figure 3.9 Biosimilar Adalimumab: Global Revenue ($m) Forecast 2016-2027
- Figure 3.10 Biosimilar Bevacizumab: Global Revenue ($m) Forecast 2016-2027
- Figure 3.11 Drivers and Restraints for the Global Biosimilar mAb market 2016-2027
- Figure 4.1 Biosimilar mAb Versions on the Market: Market Share (%) 2017
- Figure 4.2 Biosimilar mAb Versions on the Market: Market Share (%) 2020
- Figure 4.3 Biosimilar mAb Versions on the Market: Market Share (%) 2027
- Figure 4.4 Remsima/Inflectra/Flammegis (Infliximab): Revenue Forecast ($m), 2016-2027
- Figure 4.5 Remsima/Inflectra/Flammegis (Infliximab): AGR Forecast (%), 2016-2027
- Figure 4.6 Infimab (Infliximab): Revenue Forecast ($m) 2016-2027
- Figure 4.7 Infimab (Infliximab): AGR Forecast (%) 2016-2027
- Figure 4.8 Reditux (Rituximab): Revenue Forecast ($m) 2016-2027
- Figure 4.9 Reditux (Rituximab): AGR Forecast (%) 2016-2027
- Figure 4.10 Mabtas (Rituximab): Revenue Forecast ($m) 2016-2027
- Figure 4.11 Mabtas (Rituximab): AGR Forecast (%) 2016-2027
- Figure 4.12 AcellBia (Rituximab): Revenue Forecast ($m) 2016-2027
- Figure 4.13 AcellBia (Rituximab): AGR Forecast(%) 2016-2027
- Figure 4.14 MABALL (Rituximab): Revenue Forecast ($m) 2016-2027
- Figure 4.15 MABALL (Rituximab): AGR Forecast(%) 2016-2027
- Figure 4.16 Clotinab (Abciximab): Revenue Forecast ($m) 2016-2027
- Figure 4.17 Clotinab (Abciximab): AGR Forecast (%) 2016-2027
- Figure 4.18 AbcixiRel (Abciximab): Revenue Forecast ($m) 2016-2027
- Figure 4.19 AbcixiRel (Abciximab): AGR Forecast (%) 2016-2027
- Figure 4.20 Herzuma (Trastuzumab): Revenue Forecast ($m) 2016-2027
- Figure 4.21 Herzuma (Trastuzumab): AGR Forecast (%) 2016-2027
- Figure 4.22 CANMAb/Hertraz (Trastuzumab): Revenue Forecast ($m) 2016-2027
- Figure 4.23 CANMAb/Hertraz (Trastuzumab): AGR Forecast (%) 2016-2027
- Figure 4.24 BI695500 (Rituximab): Revenue Forecast ($m) 2017-2027
- Figure 4.25 BI695500 (Rituximab): AGR Forecast (%) 2018-2027
- Figure 4.26 CT-P10 (Rituximab): Revenue Forecast ($m) 2018-2027
- Figure 4.27 CT-P10 (Rituximab): AGR Forecast (%) 2019-2027
- Figure 4.28 BI695501 (Adalimumab): Revenue Forecast ($m) 2017-2027
- Figure 4.29 BI695501 (Adalimumab): AGR Forecast (%)2018-2027
- Figure 4.30 BCD-022 (Trastuzumab): Revenue Forecast ($m) 2016-2027
- Figure 4.31 BCD-022 (Trastuzumab): AGR Forecast (%) 2017-2027
- Figure 4.32 FKB327 (Adalimumab): Revenue Forecast ($m) 2017-2027
- Figure 4.33 FKB327 (Adalimumab): AGR Forecast (%) 2018-2027
- Figure 4.34 FKB238 (Adalimumab): Revenue Forecast ($m) 2020-2027
- Figure 4.35 FKB238 (Adalimumab): AGR Forecast(%) 2021-2027
- Figure 4.36 BCD-021 (Bevacizumab): Revenue Forecast ($m) 2017-2027
- Figure 4.37 BCD-021 (Bevacizumab): AGR Forecast (%) 2018-2027
- Figure 5.1 The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2016
- Figure 5.2 The Biosimilar MAb Market: National Submarket Shares (%), 2020
- Figure 5.3 The Biosimilar MAb Market: National Submarket Shares (%), 2027
- Figure 5.4 The Indian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.5 The Russian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.6 The South Korean Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.7 The Chinese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.8 The Brazilian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.9 The EU5 Biosimilar mAb Market: Grouped Revenue Forecast ($m), 2016-2027
- Figure 5.10 The EU5 Biosimilar mAb Market: Revenue Forecasts ($m) by Country, 2016-2027
- Figure 5.11 The German Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.12 The French Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.13 The UK Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.14 The Italian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.15 The Spanish Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.16 The Japanese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Figure 5.17 Biosimilar mAbs in the US: Revenue Forecast ($m), 2017-2027
- Figure 6.1 Prominent Companies in the Biosimilar mAb Industry: Share (%) of the Pipeline,
- Figure 8.1 Prominent Compounds in the Biosimilar mAb Market: Comparison of Revenues ($m), 2017, 2020 and 2027
- Figure 8.2 Forecasted Biosimilar mAbs: Comparison of Revenues ($m), 2017, 2020 and 2027
- Figure 8.3 Leading National Markets: Revenues ($m), 2017, 2020 and 2027
- Figure 8.4 Prominent Companies in the Biosimilar mAb Industry: Number of Products in Current Development or in the Pipeline, 2017
- List of Tables
- Table 1.1 Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2027
- Table 2.1 Classification of Monoclonal Antibodies
- Table 2.2 Murine Monoclonal Antibodies on the Market, 2017
- Table 2.3 Chimeric Monoclonal Antibodies on the Market, 2017
- Table 2.4 Humanised Monoclonal Antibodies on the Market, 2017
- Table 2.5 Fully Human Monoclonal Antibodies on the Market, 2017
- Table 2.6 Revenue of Originator Monoclonal Antibody Products in 2016
- Table 3.1 Biosimilar mAb Global Market: Revenue Forecast ($m), 2016-2027
- Table 3.2 Global Market for Biosimilar mAbs: Revenues ($m) and Market Shares (%) by Reference Compound, 2017, 2020 and 2027
- Table 3.3 EU and US Patent Expiry Dates for the Main mAb Reference Products
- Table 3.4 Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2027
- Table 3.5 Biosimilar Infliximab: Compounds Awaiting Approval in the Pipeline
- Table 3.6 Biosimilar Infliximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
- Table 3.7 Biosimilar Rituximab: Compounds Marketed and in the Pipeline, 2017
- Table 3.8 Biosimilar Rituximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
- Table 3.9 Biosimilar Abciximab: Compounds Marketed and in the Pipeline, 2016
- Table 3.10 Biosimilar Abciximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
- Table 3.11 Biosimilar Trastuzumab: Compounds Marketed and in the Pipeline, 2017
- Table 3.12 Biosimilar Trastuzumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
- Table 3.13 Biosimilar Adalimumab: Compounds Marketed and in the Pipeline, 2017
- Table 3.14 Biosimilar Adalimumab: Global Revenue Forecast 2016-2027
- Table 3.15 Biosimilar Bevacizumab: Compounds Marketed and in the Pipeline, 2017
- Table 3.16 Biosimilar Bevacizumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
- Table 4.1 Biosimilar mAbs on the Market in 2017: Revenues ($m) and Market Shares (%)
- Table 4.2 Remsima/Inflectra/Flammegis (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.3 Infimab (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.4 Reditux (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.5 Mabtas (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.6 Biocad Distribution Partners for AcellBia, 2016
- Table 4.7 AcellBia (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.8 MABALL (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.9 Clotinab (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.10 AbcixiRel (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.11 Herzuma (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.12 CANMAb/Hertraz (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.13 BI695500 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
- Table 4.14 CT-P10 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2018-2027
- Table 4.15 BI695501 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
- Table 4.16 BCD-022 (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
- Table 4.17 FKB327 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
- Table 4.18 FKB238 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2020-2027
- Table 4.19 BCD-021 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
- Table 5.1 Leading National Markets for the Global Biosimilar mAb Industry, 2016
- Table 5.2 Leading National Markets for the Global Biosimilar mAb Industry, 2016-2027
- Table 5.3 The Indian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.4 The Russian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.5 The South Korean Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.6 The Chinese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.7 The Brazilian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.8 The EU5 Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
- Table 5.9 The German Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.10 The French Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.11 The UK Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.12 The Italian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.13 The Spanish Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.14 The Japanese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
- Table 5.15 Finalised FDA Biosimilar Guidelines, 2015
- Table 5.16 The US Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2027
- Table 6.1 Companies in the Biosimilar mAb Industry by Number of Compounds in Development, 2017
- Table 6.2 Selected Collaborations for Biosimilar mAb Development, 2009-2017
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook